{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-025509","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-08-04T11:52:06+00:00","discovered_at":"2026-08-04T11:55:00.337428+00:00","generated_at":"2026-08-04T11:55:04.606035+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CervoMed's neflamapimod gets UK Innovation Passport for DLB treatment","bullets":["Innovation Passport awarded under UK ILAP for neflamapimod in dementia with Lewy bodies.","Program designed to accelerate time to market and facilitate patient access in the UK.","Provides coordinated guidance from MHRA, NHS, and HTA bodies (NICE, SMC, AWTTC).","DLB is the second most common progressive dementia in older people in the UK; no approved treatment.","CervoMed plans to use ILAP support to prepare for a Phase 3 trial of neflamapimod."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-025509","json":"https://secwatch.observer/filing/0001437749-26-025509.json","markdown":"https://secwatch.observer/filing/0001437749-26-025509.md","text":"https://secwatch.observer/filing/0001437749-26-025509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/0001437749-26-025509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/crvo20260803_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:55:04.606035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}